Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.
about
Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceThe Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical ReviewEffects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.Cytokine secretion from brain macrophages infected with human immunodeficiency virus in vitro and treated with raltegravir.HIV-associated neurocognitive disorders: perspective on management strategiesGenetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study.Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapyEradication of human immunodeficiency virus from brain reservoirs.Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIVUpdate on HIV-associated neurocognitive disorders.Antiretroviral bioanalysis methods of tissues and body biofluids.Role of raltegravir in HIV-1 management.CSF penetration by antiretroviral drugs.Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy.Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection.Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.Patterns of resistance development with integrase inhibitors in HIV.High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis.Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain.Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.
P2860
Q26801286-CCC450C0-AF9D-4355-BFB1-AC59D2219EA1Q28066725-DFE55D2E-9041-4BD1-87A7-75438F8382BFQ28552729-E3996729-86FF-4C77-9A9C-689BB8CDF1C0Q34202181-2CC161D1-D94B-4A5D-A73B-2CA073FA5C00Q34485748-4A3F4970-847C-4094-84B1-F6CAF53C8286Q34652590-81CA4ADA-785D-4BF7-8BDB-5A39B4697531Q35070434-0478D54F-5189-4B9A-9165-9424870C75B5Q35385630-D9590C72-C7F8-47A6-A0FA-6BFE40A4A0C7Q35532868-CD7B7BE6-9FAC-44A0-931D-3E9F9ACC6310Q35567289-65941A2F-84F1-46D2-B4B7-C921D94D81A4Q35837184-D5520CEB-53C5-4CBD-97CF-22EE5E741D45Q37200962-50B5C0BE-3BCB-40A4-B5E6-99BF6F67A240Q37332868-C9FF7D1F-F475-4CED-8858-EB487A4C793FQ38002011-80ED64B6-DD88-42B6-9671-D35614A0D6F9Q38060571-294D47E0-F9A3-413F-A726-E8928426BEE2Q38210096-B47A0831-3E3D-4BF4-8CD0-3E82F7DAC08CQ38247035-D25FE712-01BE-425B-9943-422583230035Q38527537-7C562621-105B-4685-A470-0A3190144A68Q40360498-B755E1C8-7C5E-458C-8523-1461EACAD311Q41208022-1E03BCA4-DB4C-4D75-AC3B-FA15ED1186B8Q41333285-99A2744E-8ABB-4C9B-BC3F-BDC0BA01EBE6Q41451997-720B7755-2A5C-4636-9863-7B7212FBEF7FQ41716577-F5E4CAF4-3886-41D6-8585-9EC82C539FBAQ41884572-554F4BB3-1F34-444D-90F8-06C1DF961C17Q42249892-6FDC8773-C94C-476E-912B-6D6988EE6A1CQ42689787-1711FDAB-5B03-4DA9-9AC1-B78EA4992E72Q42849831-70C565B5-9795-4835-A85A-24B742CAD9F9
P2860
Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Total raltegravir concentratio ...... entration for wild-type HIV-1.
@ast
Total raltegravir concentratio ...... entration for wild-type HIV-1.
@en
Total raltegravir concentratio ...... entration for wild-type HIV-1.
@nl
type
label
Total raltegravir concentratio ...... entration for wild-type HIV-1.
@ast
Total raltegravir concentratio ...... entration for wild-type HIV-1.
@en
Total raltegravir concentratio ...... entration for wild-type HIV-1.
@nl
prefLabel
Total raltegravir concentratio ...... entration for wild-type HIV-1.
@ast
Total raltegravir concentratio ...... entration for wild-type HIV-1.
@en
Total raltegravir concentratio ...... entration for wild-type HIV-1.
@nl
P2093
P2860
P50
P356
P1476
Total raltegravir concentratio ...... entration for wild-type HIV-1.
@en
P2093
Allen McCutchan
Ann Collier
Benjamin Gelman
Brookie M Best
Christina Marra
David Clifford
David Croteau
David Simpson
Edmund Capparelli
Florin Vaida
P2860
P304
P356
10.1128/AAC.00507-10
P407
P577
2010-09-27T00:00:00Z